Liver function may affect how PNH drug works
NCT ID NCT07152288
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study is testing a single dose of the drug HSK39297 in 24 adults with paroxysmal nocturnal hemoglobinuria (PNH) who have mild or moderate liver impairment, compared to those with normal liver function. The goal is to see how the liver affects drug levels and safety. No treatment benefit is expected from this study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HSK39297
- What this could lead to
- If successful, this study could help determine the right dose of HSK39297 for people with liver problems, making future treatments safer.
- What could go wrong
- This is a very early, small study (24 people) focused on drug processing, not on treating the disease. It may not lead to any treatment changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill tame a rare blood disease? early safety trial begins
- New drug pegcetacoplan tested in teens with rare blood disorder
- New PNH drug VSA012 enters early human testing
- New pill CMS-D017 enters first human safety trials
- Thousands with blood diseases to be tracked in massive chinese registry
- New drug SLN12140 aims to control PNH in early trial